{"transactions":[{"id":678965,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-21T23:08:21.000Z","date":"2026-08-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":175000,"derivative":{"exercise_price":1.52,"expiration_date":"2036-08-20","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001610717-26-000382","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000382/form4.xml","form_type":"4"}},{"id":893629,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-19T22:04:21.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":1436,"price":3.565,"value":5119.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation."}],"balance_after":21034,"source":{"system":"sec-edgar","filing":"0001610717-26-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000051/form4.xml","form_type":"4"}},{"id":942309,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:20:47.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":350000,"derivative":{"exercise_price":2.33,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001610717-26-000014","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000014/form4.xml","form_type":"4"}},{"id":1129478,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the\ntotal number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of\nthe Vesting Commencement Date."}],"balance_after":400000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129477,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":41250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":41250,"derivative":{"exercise_price":0.72,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129476,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":28675,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":28675,"derivative":{"exercise_price":0.72,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":28675},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129475,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":38234,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":38234,"derivative":{"exercise_price":0.72,"expiration_date":"2033-02-17","underlying":"Common Stock","underlying_shares":38234},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129474,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":85391,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from December 20, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":85391,"derivative":{"exercise_price":0.72,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":85391},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129473,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the\ntotal number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of\nthe Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129472,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129471,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":28675},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129470,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38234,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-02-17","underlying":"Common Stock","underlying_shares":38234},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1129469,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:31:14.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85391,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from December 20, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":85391},"source":{"system":"sec-edgar","filing":"0000950170-25-079926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079926/ownership.xml","form_type":"4"}},{"id":1256142,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-20T22:14:01.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":1978,"price":1.6939,"value":3350.5342,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $1.6937 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":22470,"source":{"system":"sec-edgar","filing":"0001610717-25-000030","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071725000030/form4.xml","form_type":"4"}},{"id":1264090,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":41250,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":41250,"derivative":{"exercise_price":1.69,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1264089,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":28675,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":28675,"derivative":{"exercise_price":1.69,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":28675},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1264088,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":38234,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":38234,"derivative":{"exercise_price":1.69,"expiration_date":"2033-02-17","underlying":"Common Stock","underlying_shares":38234},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1264087,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":85391,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from December 20, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":85391,"derivative":{"exercise_price":1.69,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":85391},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1264086,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":18.07,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1264085,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the \"Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":28675},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1264084,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38234,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":6.51,"expiration_date":"2033-02-17","underlying":"Common Stock","underlying_shares":38234},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1264083,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85391,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from December 20, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":4.63,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":85391},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1264082,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:04.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":400000,"derivative":{"exercise_price":1.69,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-022325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022325/ownership.xml","form_type":"4"}},{"id":1638602,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-16T21:14:03.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":41250,"derivative":{"exercise_price":18.07,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0001610717-24-000064","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000064/form4.xml","form_type":"4"}},{"id":1638601,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":20887,"kind":"person","name":"Milligan Michael Lee","position":1,"cik":"0001993953","reported_name":"Milligan Michael Lee","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-16T21:14:03.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":20625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the \"Vesting Commencement Date\"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":24448,"source":{"system":"sec-edgar","filing":"0001610717-24-000064","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000064/form4.xml","form_type":"4"}}]}